Jubilant Ingrevia Q2FY27 EBITDA rises 57% year over year
Anand Rathi reports EBITDA up 57% year over year and 7% quarter over quarter, and 12% ahead of estimates. The report cites ramp-up in Human/Cosmetic grade B3 and improved pricing in Niacinamide and Acetyls.
Anand Rathi's research report on Jubilant IngreviaJubilant Ingrevia (JUBLINGR) reported ~Rs2.1bn EBITDA (up 57% y/y and 7% q/q) in Q2FY27, 12% ahead of estimates, driven by: (a) Human/Cosmetic grade B3 ramp-up and improved pricing in Niacinamide and Acetyls aiding Nutrition and Health Solutions (NH…